REGN5069

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Healthy VolunteerOsteoarthritis of the KneePain

Phase 1

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

CompletedNCT03645746

Regeneron PharmaceuticalsHealthy Volunteer

Start: 2018-08-23End: 2019-09-30Updated: 2019-11-26

Phase 2

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

TerminatedNCT03956550

Regeneron PharmaceuticalsOsteoarthritis of the Knee, Pain

Start: 2019-05-21End: 2020-10-29Updated: 2021-07-01

Related Papers

Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain.

2023-06-265 citations